One Dose of LSD Just Beat Every Antidepressant on the Market

Response Rates That Make You Do a Double Take

Raw score improvements are one thing. But the response and remission rates tell you how many individual patients actually got meaningfully better.

At six weeks, 35% of DT120 patients hit the response threshold (meaning their depression scores dropped by at least half). Only 7% of placebo patients crossed that bar. That's a five-to-one ratio from a single dose.

Remission rates followed the same pattern. 24% of DT120 patients achieved remission, compared to just 3% on placebo. Both results were statistically significant.

Now, 35% response might not sound earth-shattering in isolation. But remember: this is after one pill. Most antidepressants need four to six weeks of daily dosing before doctors can even evaluate whether they're working. DT120 delivered these numbers from a single administration, with no mandatory psychotherapy bolted on.

The Safety Question Everyone's Asking

Whenever someone says "LSD" and "medicine" in the same sentence, the first reaction is predictable: What about the risks?

The EMERGE data offers a reassuring answer, at least so far. Definium reported no serious adverse events in the trial. There was no signal of increased suicidal thoughts or behavior, which is a critical metric in any depression study. About 99% of side effects were mild or moderate, and dropout rates were low and comparable between the drug and placebo groups.

The trial did exclude higher-risk patients: anyone with a personal or family history of psychosis, bipolar disorder, or active substance use disorders. That's standard practice for psychedelic trials, and it means the safety profile applies to a carefully screened population. Real-world use, if the drug is eventually approved, would need to maintain similarly strict guardrails.

Why This Matters Beyond One Trial

Definium (formerly MindMed, rebranded in January 2026) has been building toward this moment for years. The company already holds FDA Breakthrough Therapy Designation for DT120 in generalized anxiety disorder, earned on the strength of Phase 2b data showing 65% response rates. The EMERGE results now extend the story into depression.

The broader psychedelic psychiatry landscape has been a rollercoaster. MDMA-assisted therapy for PTSD stumbled on regulatory concerns about trial design and bias. Compass Pathways' psilocybin program has posted positive Phase 3 results for treatment-resistant depression, but its model requires intensive psychotherapy sessions alongside the drug, which creates major scalability headaches.

DT120's design sidesteps that problem entirely. It's a drug-only protocol: no six-hour therapy sessions, no specially trained therapists, no elaborate clinical infrastructure. Patients take a pill in a supervised setting and go about their lives. If that sounds more like how medicine normally works, that's exactly the point. Scalability is the difference between a therapy that helps thousands and one that helps millions.

The Road Ahead

Definium isn't done. A second pivotal MDD trial called Ascend is already planned, testing both 100-microgram and 50-microgram doses against placebo in roughly 175 patients. Two positive Phase 3 studies are typically what the FDA wants to see before approving a new drug.

The company also has two Phase 3 GAD trials (Voyage and Panorama) in the works, plus a planned Phase 3 PTSD study called Haven, targeted for 2027. And lurking in the earlier pipeline is DT402, the R-enantiomer of MDMA, being developed for social communication deficits in autism.

The FDA finalized its guidance on psychedelic clinical trials in July 2026, and a recent executive order is accelerating regulatory action on serotonin-2A agonists (the receptor class that includes LSD and psilocybin) for serious mental illness. The regulatory winds are shifting.

Jefferies reportedly suggested the stock could climb 50-100% on the strength of these MDD results. Whether that prediction holds, the clinical signal is hard to argue with.

The Bottom Line

Depression affects hundreds of millions of people worldwide, and roughly 30% of treated patients don't respond adequately to existing medications. The current standard of care is a frustrating cycle of trial and error: try one drug for six weeks, fail, switch, wait, repeat. For treatment-resistant patients, the options narrow to IV ketamine, electroshock therapy, or nasal esketamine, all with significant access and tolerability constraints.

DT120 offers something genuinely different: a single pill that works within a week and lasts for months. The effect size is larger than anything currently approved. The safety data is clean. And the delivery model is simple enough to actually scale.

We've spent decades joking about LSD. Definium just made the punchline into a prescription.

One Shot a Year: The Tiny Biotech That Just Embarrassed AbbVie's $18B Drug

A tiny biotech called Oruka just posted psoriasis clearance rates that numerically beat AbbVie's $17.6 billion juggernaut Skyrizi, and it might only need one shot a year. Wall Street is losing its mind.